Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
about
Emerging importance of ALK in neuroblastomaThe Role of PTEN in Tumor AngiogenesisAntitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitorsComplementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancerPhase II trial of sorafenib and erlotinib in advanced pancreatic cancer.Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.Combined EGFR and VEGFR versus single EGFR signaling pathways inhibition therapy for NSCLC: a systematic review and meta-analysis.Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitorsSorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growthThe monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant IIIAntitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft modelsSuppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway.S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trialCombined therapeutic efficacy of (188)Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26-luc murine colon cancer cells.Targeted therapy of hepatocellular carcinoma: present and future.Sorafenib and thyroid cancer.Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.Systematic Chemical Mutagenesis Identifies a Potent Novel Apratoxin A/E Hybrid with Improved in Vivo Antitumor Activity.Sphingosine kinase-1 activation causes acquired resistance against Sunitinib in renal cell carcinoma cells.Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment.Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells.Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.Sorafenib in the treatment of thyroid cancer.
P2860
Q26858819-77695AD3-6E71-4E75-9BAB-DFDE01F1E697Q28391620-99E97625-1420-4FAA-B992-4A2F25842D19Q28478344-F0585F62-F08C-4F04-B753-C8204444A10CQ30465168-9351DBFF-AB86-4D1A-99F3-173DACE5A97EQ33401352-EEC092EC-1C2E-40E7-92FF-B3EE7984B8D1Q33913549-3CD78B27-506F-41CD-91E6-553C88088FFBQ34241371-81521884-FEE8-4B3B-AA70-8867009BB239Q34390684-57569203-4C64-4947-A629-AF16F56F8B82Q35212644-7AC92057-5547-4651-B60D-EF53584A46BEQ35560583-8CACC7CB-AAA0-4445-AB05-10FB41ACB19DQ35928707-995703FA-99F8-4834-9D9A-B21183C5419BQ36088178-16A347C6-D081-4D6B-8B1C-AA11CA4D59F6Q36448279-F8337BF4-BF2F-4878-A151-6C2ABB8B90BFQ36560547-92755BD3-3AEE-4BC6-AA27-B858FC8A6A1DQ37268981-540E4C2B-9F1D-4696-BF88-2EC6BF8145AFQ37593264-8CCAB60C-A975-4280-B421-9601FA047E88Q37594373-29940E17-EFCF-4018-8E3F-D888F07F7AB7Q37632102-E7EBBCA2-3E35-4844-BD8C-62491CE34A29Q37722142-9DBBAE3D-2C25-4D65-9ED5-EC8475ABA01CQ37988604-C165BC1A-63D8-4CDD-80FA-42026E1EB807Q38118647-D3151FD7-2E1A-4657-9EC2-1E566EF08F2EQ38166233-EC7AB406-D7CF-4EC4-BB39-FDE7FC9FA450Q38672966-F8F0186A-E9C8-4C39-808A-81CF5AF3237BQ38730744-A67C6862-464A-4F2C-B9B2-33281BBEB79AQ39019795-16030AB2-7652-4290-B6E5-9693992C4818Q39105266-0ABC18E6-9F03-4F2B-95EF-C194F11646AFQ39253894-7F12E5DB-7C21-4C20-B0DB-62437A0C9F70Q39538184-C315E11F-3141-4183-9C0A-36BDFEDD565FQ42437883-B32CCE81-BA23-42D3-8011-9075C4071116Q46744252-BF290AC4-8E95-4759-96FF-0450EF154A7CQ47134647-DF6440DD-425D-444B-879C-1C0EE75A90B8Q49984769-2023C860-A21C-464B-AD7E-7833ECB85495Q50345931-B31949A5-7983-4A48-AD45-134D7D7970E6Q53277355-3098A243-2998-461D-A073-C29232E038B6Q54291692-F6B19F0D-E6AB-4DD1-8804-53B3D7A7ECC9Q55053748-0893544A-34A9-49E8-A1C6-9FDE4A52F99D
P2860
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Synergistic antitumor activity ...... orectal and lung cancer cells.
@en
Synergistic antitumor activity ...... orectal and lung cancer cells.
@nl
type
label
Synergistic antitumor activity ...... orectal and lung cancer cells.
@en
Synergistic antitumor activity ...... orectal and lung cancer cells.
@nl
prefLabel
Synergistic antitumor activity ...... orectal and lung cancer cells.
@en
Synergistic antitumor activity ...... orectal and lung cancer cells.
@nl
P2093
P1476
Synergistic antitumor activity ...... orectal and lung cancer cells.
@en
P2093
Anna Capasso
Concetta Tuccillo
Donata Vitagliano
Erika Martinelli
Ferdinando De Vita
Floriana Morgillo
Gabriella Rodolico
Liberato Berrino
Loredana Vecchione
Maria Pia Morelli
P304
P356
10.1158/1078-0432.CCR-10-0923
P407
P577
2010-09-01T00:00:00Z